Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Post by ontheDLon Jun 24, 2011 3:22pm

558 Views

Post# 18762950

Morning Coffee- CANACCORD WEALTH MANAGEMENT

Expert Analysis

Morning Coffee(6/22/11)"Golden Predator shares jumped after the company announced the resultsof an additional six core holes from its winter 2011 drill program atthe Carlos Zone, Grew Creek Project, Yukon. Management highlighted thatall of these holes have intersected significant mineralization including46.7m of 3.78 g/t gold beginning at a depth of 130.4m in core holeGC11-276 and 47.3m of 1.02 g/t gold from a depth of 47m in core holeGC11-275; the company also said drilling results received to datecontinue to confirm the position and orientation of veins and high-gradestockwork zones modeled from historic drill data." /pub/co/551

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario